Age-dependent resistance to excitotoxicity in Htt CAG140 mice and the effect of strain background

Journal of Huntington's Disease

Volumn 1, Issue 2, 2012, Pages 221-241

  Strong, Melissa K ^a   Southwell, Amber L ^b   Yonan, Jennifer M ^a   Hayden, Michael R ^b   Macgregor, Grant R ^c   Thompson, Leslie M ^a,c   Steward, Oswald ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cell death; Excitotoxin; genetic background; Huntington's disease; inbred mouse strains; neurodegeneration; resistance

Indexed keywords

HUNTINGTIN; KAINIC ACID; QUINOLINIC ACID; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; EFFECT SIZE; EPILEPTIC STATE; EXCITOTOXICITY; GENE EXPRESSION; HETEROZYGOSITY; HOMOZYGOSITY; HUNTINGTON CHOREA; MALE; MOUSE; MOUSE STRAIN; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STRAIN DIFFERENCE; STRIATAL NEURODEGENERATION; STRIATE CORTEX; AGING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COMPARATIVE STUDY; CORPUS STRIATUM; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; PATHOLOGY; SPECIES DIFFERENCE; TRANSGENIC MOUSE;

AGING; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; QUINOLINIC ACID; SPECIES SPECIFICITY;

EID: 84892595897     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-129005     Document Type: Article

References (64)

1. DiFiglia M. Excitotoxic injury of the neostriatum: A model for Huntington's disease. Trends Neurosci. 1990;13(7):286-9.
2. Gil JM,RegoAC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci. 2008;27(11):2803-20. (Pubitemid 351832229)
3. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30(4):379-87.
4. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 1986;321(6066):168-71. (Pubitemid 16022019)
5. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, et al. Increased sensitivity to N-methyl-Daspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 2002;33(6):849-60. (Pubitemid 34246352)
6. Zeron MM, Fernandes HB, Krebs C, Shehadeh J,Wellington CL, Leavitt BR, et al. Potentiation of NMDA receptormediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol Cell Neurosci. 2004;25(3):469-79. (Pubitemid 38366412)
7. McLin JP, Thompson LM, Lusis AJ, Davis RC, Steward O. Genes on distal chromosome 18 determine vulnerability to excitotoxic neurodegeneration following status epilepticus, but not striatal neurodegeneration induced by quinolinic acid. Neurobiol Dis. 2008;29(3):391-9. (Pubitemid 351258349)
8. Schauwecker PE, Steward O. Genetic determinants of susceptibility to excitotoxic cell death: Implications for gene targeting approaches. Proc Natl Acad Sci USA. 1997;94(8):4103-8. (Pubitemid 27180506)
9. McLin JP, Steward O. Comparison of seizure phenotype and neurodegeneration induced by systemic kainic acid in inbred, outbred, and hybrid mouse strains. Eur J Neurosci. 2006;24(8):2191-202. (Pubitemid 44622340)
10. McLin JP, Thompson LM, Steward O. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains. Eur J Neurosci. 2006;24(11):3134-40. (Pubitemid 44952645)
11. Schauwecker PE, Williams RW, Santos JB. Genetic control of sensitivity to hippocampal cell death induced by kainic acid: A quantitative trait loci analysis. J Comp Neurol. 2004;477(1):96-107. (Pubitemid 39038182)
12. Stevens JC, Banks GT, Festing MF, Fisher EM. Quiet mutations in inbred strains of mice. Trends Mol Med. 2007;13(12):512-9. (Pubitemid 350130346)
13. Taft RA, Davisson M, Wiles MV. Know thy mouse. Trends Genet. 2006;22(12):649-53. (Pubitemid 44738127)
14. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28(24):6182-95.
15. Heng MY, Tallaksen-Greene SJ, Detloff PJ, Albin RL. Longitudinal evaluation of the Hdh(CAG)150 knockin murine model of Huntington's disease. J Neurosci. 2007;27(34):8989-98. (Pubitemid 47312064)
16. Hodgson JG, Agopyan N, Gutekunst C-A, Leavitt BR, LePiane F, Singaraja R, et al. AYACmouse model for Huntington's Disease with full-length mutant Huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999;20:181-92. (Pubitemid 29262475)
17. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of theHDgene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493-506. (Pubitemid 26374323)
18. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol. 2003;465(1):11-26. (Pubitemid 37075677)
19. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet. 1999;8(3):397-407. (Pubitemid 29097327)
20. Wheeler VC, Auerbach W, White JK, Srinidhi J, Auerbach A, Ryan A, et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet. 1999;8(1):115-22. (Pubitemid 29039056)
21. Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, et al. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull. 2007;72(2-3):83-97. (Pubitemid 46367466)
22. Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet. 2000;9(4):503-13. (Pubitemid 30154008)
23. Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, Levine MS, et al. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience. 2008;157(1):280-95.
24. Li JY, Popovic N, Brundin P. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx. 2005;2(3):447-64. (Pubitemid 41444878)
25. Van Raamsdonk JM, Warby SC, Hayden MR. Selective degeneration in YAC mouse models of Huntington disease. Brain Res Bull. 2007;72(2-3):124-31. (Pubitemid 46367458)
26. Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, et al. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis. 2007;26(1):189-200. (Pubitemid 46436497)
27. Cowin RM, Bui N, Graham D, Green JR, Yuva-Paylor LA, Weiss A, et al. Genetic background modulates behavioral impairments in R6/2 mice and suggests a role for dominant genetic modifiers in Huntington's disease pathogenesis. Mamm Genome. 2012;23(5-6):367-77.
28. Jarabek BR, Yasuda RP, Wolfe BB. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain. 2004;127(Pt 3):505-16. (Pubitemid 38295468)
29. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad SciUS A. 2005;102(32):11402-7. (Pubitemid 41153832)
30. Petersen A, Chase K, Puschban Z, DiFiglia M, Brundin P, Aronin N. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Exp Neurol. 2002;175(1):297-300. (Pubitemid 34507930)
31. Hansson O, Petersen A, Leist M, Nicotera P, Castilho RF, Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci U S A. 1999;96(15):8727-32. (Pubitemid 29354859)
32. Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, Castilho RF, et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci. 2001;14(9): 1492-504. (Pubitemid 35463716)
33. Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci. 2009;29(7):2193-204.
34. Levine MS, Klapstein GJ,Koppel A, Gruen E, Cepeda C,Vargas ME, et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res. 1999;58(4):515-32. (Pubitemid 29530435)
35. Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, et al. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice. Hum Mol Genet. 2006;15(12):2015-24. (Pubitemid 43983275)
36. Schmued LC, Hopkins KJ. Fluoro-Jade B: A high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 2000;874(2):123-30.
37. Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19(12):2178-85.
38. Wellington CL, Ellerby LM, Gutekunst CA, Rogers D,Warby S, Graham RK, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci. 2002;22(18):7862-72. (Pubitemid 35379091)
39. Wanker EE, Scherzinger E, Heiser V, Sittler A, Eickhoff H, Lehrach H. Membrane filter assay for detection of amyloidlike polyglutamine-containing protein aggregates. Methods Enzymol. 1999;309:375-86. (Pubitemid 29446461)
40. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 1997;90(3):549-58. (Pubitemid 27347244)
41. Ryu JK, McLarnon JG. VEGF receptor antagonist Cyclo-VEGI reduces inflammatory reactivity and vascular leakiness and is neuroprotective against acute excitotoxic striatal insult. J Neuroinflammation. 2008;5:18.
42. Steward O, Torre ER, Tomasulo R, Lothman E. Neuronal activity up-regulates astroglial gene expression. Proc Natl Acad Sci U S A. 1991;88(15):6819-23. (Pubitemid 21915041)
43. Kim SH, Thomas CA, Andre VM, Cummings DM, Cepeda C, Levine MS, et al. Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro. 2011;3(3):e00060.
44. Freund TF, Ylinen A, Miettinen R, Pitkanen A, Lahtinen H, Baimbridge KG, et al. Pattern of neuronal death in the rat hippocampus after status epilepticus. Relationship to calcium binding protein content and ischemic vulnerability. Brain Res Bull. 1992;28(1):27-38.
45. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805-10. (Pubitemid 39434070)
46. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, et al. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J Neurosci. 1999; 19(7):2522-34. (Pubitemid 29162401)
47. Silver LM. Mouse Genetics Concepts and Applications. In Concepts and Applications. Oxford, University Press; 1995.
48. Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, et al. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem. 2006;96(4):1121-9.
49. Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMCNeurosci. 2006;7:80.
50. Lajoie P, Snapp EL. Formation and toxicity of soluble polyglutamine oligomers in living cells. PLoS One. 2010;5(12):e15245.
51. Nucifora LG, Burke KA, Feng X, Arbez N, Zhu S, Miller J, et al. Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem. 2012;287(19):16017-28.
52. Zuchner T, Brundin P. Mutant huntingtin can paradoxically protect neurons from death. Cell Death Differ. 2008;15(3):435-42. (Pubitemid 351267294)
53. Brooks SP, Jones L, Dunnett SB. Comparative analysis of pathology and behavioural phenotypes in mouse models of Huntington's disease. Brain Res Bull. 2012;88(2-3):81-93.
54. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537-48. (Pubitemid 27347243)
55. Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol. 2011;7(12): 925-34.
56. Cummings DM, Cepeda C, Levine MS. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro. 2010;2(3):e00036.
57. Cummings DM, Andre VM, Uzgil BO, Gee SM, Fisher YE, Cepeda C, et al. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci. 2009;29(33):10371-86.
58. Joshi PR, Wu NP, Andre VM, Cummings DM, Cepeda C, Joyce JA, et al. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci. 2009;29(8):2414-27.
59. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 2010;65(2):178-90.
60. Milnerwood AJ, Raymond LA. Early synaptic pathophysiology in neurodegeneration: Insights from Huntington's disease. Trends Neurosci. 2010;33(11):513-23.
61. Li SH, Li XJ. Huntingtin and its role in neuronal degeneration. Neuroscientist. 2004;10(5):467-75.
62. Saavedra A, Giralt A, Rue L, Xifro X, Xu J, Ortega Z, et al. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: A STEP in the resistance to excitotoxicity. J Neurosci. 2011;31(22):8150-62.
63. Choi YS, Lin SL, Lee B, Kurup P, Cho HY, Naegele JR, et al. Status epilepticus-induced somatostatinergic hilar interneuron degeneration is regulated by striatal enriched protein tyrosine phosphatase. J Neurosci. 2007;27(11):2999-3009. (Pubitemid 46438970)
64. Liu L, Hamre KM, Goldowitz D. Kainic Acid-Induced Neuronal Degeneration in Hippocampal Pyramidal Neurons Is Driven by Both Intrinsic and Extrinsic Factors: Analysis of FVB/N?C57BL/6 Chimeras. J Neurosci. 2012;32(35):12093-101.